Many are called, few are chosen: the role of science in drug development decisions

Linde Colen, Rene Belderbos, Stijn Kelchtermans and Bart Leten ()
Additional contact information
Linde Colen: Hasselt University
Stijn Kelchtermans: Hasselt University
Bart Leten: Hasselt University

The Journal of Technology Transfer, 2024, vol. 49, issue 2, No 4, 492-517

Abstract: Abstract Pharmaceutical firms are extremely selective in deciding which patented drug candidates are taken up into clinical development, given the high costs and risks involved. We argue that the scientific base of drug candidates, and who was responsible for that scientific research, are key antecedents of take-up into clinical trials and whether the patent owner (‘internal take-up’) or another firm (‘external take-up’) leads the clinical development effort. We hypothesize that patented drug candidates that refer to scientific research are more likely to be taken up in development, and that in-house conducted scientific research is predominantly associated with internal take-up due to the ease of knowledge transfer within the firm. Examining 18,360 drug candidates patented by 136 pharmaceutical firms we find support for these hypotheses. In addition, drug candidates referring to in-house scientific research exhibit a higher probability of eventual drug development success. Our findings underline the importance of a ‘rational drug design’ approach that explicitly builds on scientific research. The benefits of internal scientific research in clinical development highlight the potential downside of pervasive organizational specialization in the life sciences in either scientific research or clinical development.

Keywords: R&D; Patents; Science; Drug development; Pharmaceutical industry (search for similar items in EconPapers)
JEL-codes: O31 O32 (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10961-022-09982-6 Abstract (text/html)
Access to full text is restricted to subscribers.

Related works:
Working Paper: Many are called, few are chosen: The role of science in drug development decisions (2022)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:kap:jtecht:v:49:y:2024:i:2:d:10.1007_s10961-022-09982-6

Ordering information: This journal article can be ordered from
http://www.springer. ... nt/journal/10961/PS2

DOI: 10.1007/s10961-022-09982-6

Access Statistics for this article

The Journal of Technology Transfer is currently edited by Albert N. Link, Donald S. Siegel, Barry Bozeman and Simon Mosey

More articles in The Journal of Technology Transfer from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().